| Amantadine | ADAMAS Pharma | ||
| 68.5mg; Capsule, Extended Release |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
None | ||
| Indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. | |||
|
Yes
| |||
| Gocovri | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ***** ****** | *** \ ********* | *** **, **** | ******* | ******** | ** *** **, **** |
| Amantadine | ADAMAS Pharma | ||
| 137 mg Extended release, Capsule, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| Indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. | |||
|
Yes
| |||
| Gocovri | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ****** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** ****** | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* | ********* ******* ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** \ ********* | **** **, **** | ******* | ********* ******** | ** ***** *, **** |
| ***** ****** | ** \ ** | *** **, **** | ******* | ********* ******** | ** ***** *, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|